Psychemedics (PMDI) Stock Overview
Engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
PMDI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Psychemedics Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.40 |
| 52 Week High | US$2.50 |
| 52 Week Low | US$1.33 |
| Beta | 0.73 |
| 1 Month Change | 9.09% |
| 3 Month Change | 50.94% |
| 1 Year Change | 4.35% |
| 3 Year Change | -51.22% |
| 5 Year Change | -63.64% |
| Change since IPO | -77.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| PMDI | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 0% | -0.4% | 1.1% |
| 1Y | 4.3% | 16.3% | 28.7% |
Return vs Industry: PMDI underperformed the US Healthcare industry which returned 16.3% over the past year.
Return vs Market: PMDI underperformed the US Market which returned 28.7% over the past year.
Price Volatility
| PMDI volatility | |
|---|---|
| PMDI Average Weekly Movement | 15.6% |
| Healthcare Industry Average Movement | 7.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PMDI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PMDI's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 101 | Brian Hullinger | www.psychemedics.com |
Psychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. The company provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising aka K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, fentanyl and fentanyl analogs, and alcohol. Its testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time.
Psychemedics Corporation Fundamentals Summary
| PMDI fundamental statistics | |
|---|---|
| Market cap | US$14.69m |
| Earnings (TTM) | -US$1.86m |
| Revenue (TTM) | US$19.69m |
Is PMDI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PMDI income statement (TTM) | |
|---|---|
| Revenue | US$19.69m |
| Cost of Revenue | US$12.58m |
| Gross Profit | US$7.10m |
| Other Expenses | US$8.96m |
| Earnings | -US$1.86m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.30 |
| Gross Margin | 36.07% |
| Net Profit Margin | -9.45% |
| Debt/Equity Ratio | 4.1% |
How did PMDI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/24 05:41 |
| End of Day Share Price | 2026/05/15 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Psychemedics Corporation is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Wallace | Sidoti & Company, LLC |